Upcoming Studies


A multicenter, randomised, double-blind, phase III trial of nintedanib (BIBF 1120) or placebo in combination with carboplatin and paclitaxel in patients with platinum sensitive recurrent ovarian cancer.

Learn More ->


Genetic variability in drug transport, metabolism or DNA repair effecting toxicity of chemotherapy in ovarian cancer.

Learn More ->


A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.